Catatonic schizophrenia was once considered a distinct subtype of schizophrenia, defined by striking motor and behavioral disturbances such as prolonged immobility, mutism, and rigid posturing. The diagnosis existed for over a century, but modern psychiatry has moved away from it. The DSM-5, published in 2013, deleted “schizophrenia, catatonic type” as a standalone diagnosis, reclassifying catatonia as a specifier that can be applied across many psychiatric and medical conditions. That shift reflects decades of clinical evidence showing that catatonia appears far more often alongside mood disorders, neurological conditions, and medical illnesses than it does alongside schizophrenia alone. The old label still shows up in clinical conversations and in the ICD-10, but understanding why it fell out of favor, and what replaced it, matters for anyone trying to make sense of this condition.
How Catatonia Became Fused With Schizophrenia
The German psychiatrist Karl Kahlbaum first described catatonia in 1874 as a distinct motor dysregulation syndrome, a disease in its own right defined by phases of stupor, excitement, and abnormal posturing.1PubMed Central. Catatonia is not schizophrenia: Kraepelin’s error and the need to recognize catatonia as an independent syndrome in medical nomenclature Kahlbaum recognized that patients with catatonia could have a range of outcomes and underlying causes. That nuance was lost within a few decades. Emil Kraepelin, the enormously influential classifier of mental illness, folded catatonia into his concept of dementia praecox (later renamed schizophrenia), narrowing Kahlbaum’s broad concept by emphasizing psychotic symptoms and poor prognosis while dropping the original phasic course.2Schizophrenia Bulletin. The Development of Kraepelin’s Mature Diagnostic Concept of Catatonic Dementia Praecox: A Close Reading of Relevant Texts Eugen Bleuler reinforced this association, and for the entire twentieth century catatonia was viewed primarily as a subtype of schizophrenia in major classification systems.3PubMed. The different conceptions of catatonia: historical overview and critical discussion
This historical accident had real consequences. Clinicians who saw catatonic features in a patient with depression or bipolar disorder sometimes hesitated to make the diagnosis because catatonia “belonged” to schizophrenia. Patients with medical causes of catatonia, from autoimmune encephalitis to metabolic crises, were at risk of being misidentified as having a primary psychotic illness. The DSM-5 revision explicitly corrected this by deleting the catatonic subtype of schizophrenia and instead proposing catatonia as a specifier applicable across ten principal diagnoses.4PubMed Central. Catatonia from its creation to DSM-V: Considerations for ICD
What Catatonia Looks Like
Catatonia is not a single symptom but a syndrome with a wide range of motor and behavioral features. The retarded or stuporous form, which is the image most people associate with the term, involves a person who stops moving, stops speaking, and may hold bizarre postures for hours. Waxy flexibility is one of the most recognized signs: a clinician can move a patient’s limb into an unusual position, feel slight resistance, and then watch the patient maintain that posture as though they were made of wax.5PubMed Central. The Role of Metabolic Disorders in the Development of Waxy Flexibility in Patients with Catatonic Schizophrenia Mutism, negativism (active resistance to instructions or attempts at movement), and staring are other hallmarks of this presentation.
There is also an excited form of catatonia that looks almost nothing like the stereotypical image. In this variant, the person shows purposeless, frenzied motor activity that is not driven by external stimulation. They may repeat words or phrases endlessly (verbigeration), mimic the movements or speech of others (echopraxia and echolalia), or cycle between agitation and sudden stillness. Both forms can alternate in the same person during the same episode, which contributes to the difficulty of recognizing catatonia when it does not match the classic “frozen” picture.
Why It Happens
The dominant theory involves disruption of a brain signaling system called GABA, which is the primary brake on neural activity. Reduced GABA function in the circuit running between the basal ganglia, the thalamus, and the cortex appears to underlie the motor disturbances. The strongest evidence for this hypothesis comes from treatment itself: benzodiazepines, which boost GABA activity, produce a dramatic and often rapid reversal of catatonic symptoms in many patients. Neuroimaging studies have further confirmed GABA-A receptor alterations in people with catatonia.6Frontiers. Neurobiological Approach of Catatonia and Treatment Perspectives
Glutamate, the brain’s main excitatory neurotransmitter, also appears to play a role. The interplay between reduced GABA signaling and excess or dysregulated glutamate activity may account for the varied motor symptoms, from frozen immobility to frenzied excitement. Neuroimaging of patients in akinetic (immobile) catatonic states has revealed abnormal activation patterns in the orbitofrontal cortex and disrupted connections between frontal regions and the premotor cortex, suggesting that catatonia involves a breakdown in how emotional processing is translated into motor output.7Schizophrenia Bulletin. Orbitofrontal Cortical Dysfunction in Akinetic Catatonia: A Functional Magnetic Resonance Imaging Study During Negative Emotional Stimulation
How It Is Diagnosed
Recognizing catatonia depends on a structured bedside examination rather than a blood test or brain scan. The most widely used tool is the Bush-Francis Catatonia Rating Scale (BFCRS), a 23-item instrument that systematically checks for signs including immobility, mutism, staring, posturing, grimacing, stereotypy, and waxy flexibility. Its inter-rater reliability is high, meaning different clinicians examining the same patient tend to arrive at the same score.8PubMed. Catatonia. I. Rating scale and standardized examination The scale has been validated in multiple languages and clinical populations.9PubMed. Development and validation of the Bush-Francis Catatonia Rating Scale – Brazilian version A revised version with binary scoring (present versus absent, rather than graded severity) has been tested in chronic schizophrenia patients and showed improved measurement properties for that group.10PubMed Central. Rating catatonia in patients with chronic schizophrenia: Rasch analysis of the Bush-Francis Catatonia Rating Scale
In practice, though, catatonia remains underdiagnosed. The excited form is frequently mistaken for acute psychotic agitation, and the retarded form can be confused with severe depression, delirium, or medication side effects. One important diagnostic clue is dysautonomia, which includes abnormalities in heart rate, blood pressure, sweating, and temperature regulation. In some clinical settings, the recognition of dysautonomic features is what first triggers formal catatonia assessment.11PubMed Central. Catatonia in anti-NMDA receptor encephalitis: a case series and approach to improve outcomes with electroconvulsive therapy
The Lorazepam Challenge and First-Line Treatment
The most straightforward test and treatment for catatonia is a dose of intravenous lorazepam. In what is called the “lorazepam challenge,” a clinician administers a dose (commonly around 2 to 4 mg) and watches for improvement in catatonic signs within minutes to hours. A positive response, where the patient begins to speak, move, or engage, strongly supports the diagnosis and points the way toward ongoing benzodiazepine therapy.12PubMed Central. Lorazepam challenge test: A unique clinical response in catatonia Research suggests that the lorazepam challenge is a good predictor of response during the first week of treatment, though its predictive value for longer-term outcomes decreases.13PubMed Central. The retrospective and observational study of catatonia – Diagnosis, course of illness, and the response to lorazepam – in a tertiary health-care center
When benzodiazepines fail or produce only a partial response, electroconvulsive therapy (ECT) is typically the next step. ECT has a long track record of effectiveness in catatonia, including cases that do not respond to medication. For the small number of patients who are resistant to both benzodiazepines and ECT, a handful of alternatives have been tried. A review of case reports identified amantadine, memantine, certain antipsychotics (particularly aripiprazole and clozapine), and lorazepam augmentation alongside ECT as approaches used in these difficult situations.14PubMed. Electroconvulsive Therapy-Resistant Catatonia: Case Report and Literature Review Amantadine and memantine work through glutamate antagonism, and a review of 25 cases treated with either agent found indirect evidence that they may help in patients who do not respond to standard therapy.15PubMed. Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes
When Antipsychotics Become the Problem
Here is where things get especially tricky for people whose catatonia occurs alongside schizophrenia. Antipsychotics are the mainstay of schizophrenia treatment, but they can also induce or worsen catatonic states. These drugs are the primary trigger for neuroleptic malignant syndrome (NMS), a potentially fatal reaction characterized by high fever, muscle rigidity, altered consciousness, and autonomic instability.16PubMed Central. Antipsychotic-induced catatonia and neuroleptic malignant syndrome: the dark side of the moon The clinical overlap between NMS and malignant catatonia is substantial and creates real diagnostic dilemmas. Both can present with rigidity, mutism, fever, and elevated heart rate. Case reports describe patients initially treated for one condition whose diagnosis was changed to the other when they failed to respond as expected.17PubMed Central. Malignant Catatonia Versus Neuroleptic Malignant Syndrome 18PubMed Central. Catatonia versus neuroleptic malignant syndrome: the diagnostic dilemma and treatment
The practical consequence is that a person with schizophrenia who develops catatonia faces a medication paradox. The very drugs used to manage psychotic symptoms can provoke or worsen the catatonic episode. Treatment typically involves stopping or reducing antipsychotics, initiating benzodiazepines, and carefully reintroducing antipsychotics only after the catatonic symptoms have resolved. Clozapine and aripiprazole, which have somewhat different pharmacological profiles from older antipsychotics, are sometimes preferred when antipsychotic therapy must be resumed.
Medical Complications of Prolonged Catatonia
Catatonia is not just a psychiatric curiosity. Prolonged immobility creates a cascade of medical risks that can be life-threatening. Medical complications have been reported in up to a quarter of patients with catatonia, including deep vein thrombosis, pulmonary embolism, nutritional deficiencies, rhabdomyolysis (muscle breakdown), pressure ulcers, deconditioning, and contractures.19American Journal of Medicine Open. Catatonia: A Narrative Review for Hospitalists Deep vein thrombosis is a particularly well-documented risk of prolonged catatonic immobility.20General Hospital Psychiatry. A case of deep venous thrombosis following protracted catatonic immobility recovered with electroconvulsive therapy: the relevance for an early intervention
The mortality implications are stark. A study comparing schizophrenia patients with and without catatonic stupor found that the catatonia group had nearly five times the odds of dying, along with significantly elevated rates of pneumonia, sepsis, kidney failure, disseminated intravascular coagulation, and other serious medical complications.21PubMed Central. Catatonic Stupor in Schizophrenic Disorders and Subsequent Medical Complications and Mortality This is why speed of diagnosis and treatment matters so much. Every day a patient spends immobile and mute carries accumulating physical risk on top of the psychiatric emergency.
Recurrence and Long-Term Outlook
Catatonia is not always a one-time event. Studies following patients over years find recurrence rates that are higher than many clinicians expect. One large study reported that about half of patients relapsed over a median follow-up of roughly two and a half years, with the highest risk concentrated within the first two years after the initial episode. Antipsychotic prescriptions at discharge were associated with a reduction in relapse risk of about 40%.22JAMA Psychiatry. Risk Factors for Catatonia Relapse in Psychotic and Affective Disorders A separate study with a longer follow-up period (median of about six years) found a recurrence rate of roughly 31%, with benzodiazepine use consistently protective against relapse. That study also revealed a more complex picture for antipsychotics: they appeared to lower recurrence risk in the first two months but were associated with increased risk of recurrence thereafter.23PubMed Central. Catatonia treatments and risk of recurrence
The tension between those two findings on antipsychotics reflects a genuine uncertainty in the field. The patient populations, follow-up durations, and analytic methods differed, and antipsychotic type and dosing varied. What seems clear is that benzodiazepines are reliably helpful for preventing relapse. Whether and when to use antipsychotics for maintenance depends heavily on the individual clinical picture.
The long-term functional outlook for patients who have experienced catatonia also warrants attention. A five-year follow-up study found that patients with a history of catatonia had significantly lower functioning scores than matched patients without catatonia, along with a higher proportion of treatment-resistant cases (roughly a quarter versus about 6% of non-catatonic patients). Patients in the catatonic group also had more hospital readmissions, and those with elevated inflammatory markers fared worse still.24PubMed. The long-term clinical and functional outcomes of psychiatric patients with catatonia: A 5-year follow-up
Catatonia in Autism and Neurodevelopmental Conditions
One of the most underrecognized settings for catatonia is autism spectrum disorder (ASD). A meta-analysis found that about 10% of individuals with ASD meet criteria for catatonia, with onset typically in late adolescence, peaking between ages 15 and 19.25PubMed Central. Catatonia in autism spectrum disorders: A systematic review and meta-analysis That figure is roughly similar to the prevalence of catatonia across psychiatric and medical conditions more generally, but catatonia in autism is harder to spot. Core ASD features like mutism, stereotyped behaviors, echolalia, and resistance to direction overlap substantially with catatonic symptoms. In people with intellectual disability, who represent a large share of those with autistic catatonia, communication difficulties make standard assessments even harder to apply.26Journal of the American Academy of Child & Adolescent Psychiatry. Catatonia in Autism and Neurodevelopmental Disorders: A Scoping Review for Advancing Identification, Practice, and Research
The practical warning here is that a sudden worsening of function in an autistic teenager or young adult, new immobility, loss of previously acquired skills, or new refusal to eat, should prompt clinicians to consider catatonia rather than assuming it is simply a behavioral deterioration related to the underlying autism. The treatments (benzodiazepines and ECT) are the same, and delay carries the same medical risks.
What Patients Remember
There is a common assumption that people in catatonic states are “not there,” essentially unconscious or unaware of their surroundings. Research into the subjective experiences of patients recovering from catatonia tells a different story. An exploratory study of acute psychiatric inpatients found that subjective experiences during catatonic episodes were mostly negative and, strikingly, remained relatively stable even after the motor symptoms resolved.27PubMed. Subjective experiences of catatonia in acute psychiatric inpatients: An exploratory study Patients recall fear, confusion, and a sense of being trapped in their bodies. This finding has implications for how clinical teams interact with catatonic patients: the person may well be aware of what is happening around them and what is being said, even when they appear entirely unresponsive.
Legal Obstacles to Emergency ECT
Malignant catatonia, the form involving high fever, autonomic instability, and risk of organ failure, can be fatal without aggressive treatment. ECT is often the most effective intervention for cases that do not respond to benzodiazepines. But ECT is one of the most heavily regulated treatments in medicine, and catatonic patients frequently cannot give consent because their illness renders them mute and immobile. In some U.S. states, the regulations around involuntary ECT are more restrictive than those for other life-saving medical procedures. A review examining California, Texas, and New York found that exacting legal mandates for involuntary ECT can delay or prevent treatment in emergency situations where the patient’s life is at risk.28Harvard Review of Psychiatry. Practical and Legal Challenges to Electroconvulsive Therapy in Malignant Catatonia Court-ordered ECT may ultimately be required, and the time needed to navigate that process can be the difference between recovery and a medical catastrophe. Clinicians treating malignant catatonia often describe a frustrating race between clinical urgency and legal procedure, one that does not have an easy resolution given the legitimate concerns about patient autonomy that motivate ECT oversight in the first place.